PROSTATE cancer is the second leading cause of cancer death worldwide amongst men, however recent research has revealed that far more patients are diagnosed than die of the disease. In 2022, there ...
A study shows that combining dual immunotherapy with chemotherapy improves outcomes for metastatic non-squamous NSCLC patients with STK11 and KEAP1 mutations. Learn more ...